

# Bruce Green

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1735637/publications.pdf>

Version: 2024-02-01

30  
papers

1,853  
citations

567281

15  
h-index

454955

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2081  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of Lean Bodyweight. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1051-1065.	3.5	707
2	What is the best size descriptor to use for pharmacokinetic studies in the obese?. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 119-133.	2.4	306
3	The Relationship between Drug Clearance and Body Size. <i>Clinical Pharmacokinetics</i> , 2012, 51, 319-330.	3.5	131
4	A Standard Weight Descriptor for Dose Adjustment in the Obese Patient. <i>Clinical Pharmacokinetics</i> , 2004, 43, 1167-1178.	3.5	91
5	The effects of obesity on drug pharmacokinetics in humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 697-706.	3.3	82
6	Development of a dosing strategy for enoxaparin in obese patients. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 96-103.	2.4	81
7	Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5315-5324.	3.2	62
8	Lean body mass normalizes the effect of obesity on renal function. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 964-965.	2.4	58
9	Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2003, 30, 145-161.	1.8	53
10	Caution when lean body weight is used as a size descriptor for obese subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 0743-0744.	4.7	41
11	Encouraging the Move Towards Predictive Population Models for the Obese Using Propofol as a Motivating Example. <i>Pharmaceutical Research</i> , 2009, 26, 1626-1634.	3.5	31
12	Reporting a Population Pharmacokineticâ€“Pharmacodynamic Study: A Journalâ€™s Perspective. <i>Clinical Pharmacokinetics</i> , 2014, 53, 111-122.	3.5	30
13	Modelling the occurrence and severity of enoxaparinâ€“induced bleeding and bruising events. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 700-711.	2.4	19
14	Current dosing of lowâ€“molecularâ€“weight heparins does not reflect licensed product labels: an international survey. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 520-528.	2.4	17
15	Informative study designs to identify true parameterâ€“covariate relationships. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 147-163.	1.8	16
16	Anesthetizing the Obese. <i>Anesthesia and Analgesia</i> , 2011, 113, 1-3.	2.2	16
17	Individualized Dosing of Enoxaparin for Subjects With Renal Impairment Is Superior to Conventional Dosing at Achieving Therapeutic Concentrations. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 482-488.	2.0	14
18	Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 165-176.	2.4	13

#	ARTICLE	IF	CITATIONS
19	Determination of a suitable voriconazole pharmacokinetic model for personalised dosing. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 165-177.	1.8	13
20	Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 593-599.	1.9	11
21	A Study to Determine the Importance of Ward Pharmacists Reviewing Discharge Prescription. <i>Journal of Pharmacy Practice and Research</i> , 2001, 31, 300-302.	0.2	10
22	Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass. <i>Clinical Pharmacokinetics</i> , 2020, 59, 475-483.	3.5	9
23	Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine. <i>Clinical Pharmacokinetics</i> , 2017, 56, 525-536.	3.5	8
24	Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients. <i>HIV Clinical Trials</i> , 2013, 14, 92-98.	2.0	7
25	Quantifying Pain Relief Following Administration of a Novel Formulation of Paracetamol (Acetaminophen). <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1406-1413.	2.0	5
26	Population Pharmacokinetics of Rabeprazole and Dosing Recommendations for the Treatment of Gastroesophageal Reflux Disease in Children Aged 1-11 Years. <i>Clinical Pharmacokinetics</i> , 2014, 53, 943-957.	3.5	5
27	The Impact of Model-Misspecification on Model Based Personalised Dosing. <i>AAPS Journal</i> , 2016, 18, 1244-1253.	4.4	5
28	Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	5
29	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-Infected, Treatment-Experienced Children and Adolescents in PIANO. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1395-1405.	2.0	4
30	Evaluating Lean Liver Volume as a Potential Scaler for In Vitro-In Vivo Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine. <i>Current Drug Metabolism</i> , 2020, 21, 746-750.	1.2	3